Search results

Sort By:

Limit search:

An adverse events potential costs analysis based on Drug Programs in Poland. Dermatology focus

100%

Szkultecka-Debek M., Drozd M., Kiepurska N., Janowska A., Paprzycki P., Paluchowska B.

vol. 27

issue 3

183-186

The aim of the project, carried out within the Polish Society for Pharmacoeconomics (PTFE), was to estimate the potential costs of treatment of the side effects which (theoretically) may occur as a result of treatments for the selected diseases. This paper deals solely with dermatology related events. Herein, several Drug Programs financed by the National Health Fund in Poland, in 2012, were analyzed. The adverse events were selected based on the Summary of Product Characteristics of the chosen products. We focused the project on those potential adverse events which were defined in SPC as frequent and very frequent. The results are presented according to their therapeutic areas, and in this paper, the focus is upon that which is related to dermatology. The events described as ‘very common’ had an incidence of ≥ 1/10, and that which is ‘common’ - ≥ 1/100, <1 /10. In order to identify the resources used, we, with the engagement of clinical experts, performed a survey. In our work, we employed only the total direct costs incurred by the public payer, based on valid individual cost data in February 2014. Moreover, we calculated the total spending from the public payer’s perspective, as well as the patient’s perspective, and the percentage of each component of the total cost in detail. The paper, thus, informs the reader of the estimated costs of treatment of side effects related to the dermatologic symptoms and reactions. Based on our work, we can state that the treatment of skin adverse drug reactions generates a significant cost - one incurred by both the public payer and the patient.

An analysis of potential costs of adverse events based on Drug Programs in Poland. Pulmonology focus

84%

Szkultecka-Debek M., Drozd M., Jahnz-Rozyk K., Kiepurska N., Mazurek J., Janowska A., Paprzycki P., Adamczyk-Korbel M., Paluchowska B., Drozd K.

vol. 27

issue 1

32-36

The project was performed within the Polish Society for Pharmacoeconomics (PTFE). The objective was to estimate the potential costs of treatment of side effects, which theoretically may occur as a result of treatment of selected diseases. We analyzed the Drug Programs financed by National Health Fund in Poland in 2012 and for the first analysis we selected those Programs where the same medicinal products were used. We based the adverse events selection on the Summary of Product Characteristics of the chosen products. We extracted all the potential adverse events defined as frequent and very frequent, grouping them according to therapeutic areas. This paper is related to the results in the pulmonology area. The events described as very common had an incidence of ≥ 1/10, and the common ones ≥ 1/100, <1/10. In order to identify the resources used, we performed a survey with the engagement of clinical experts. On the basis of the collected data we allocated direct costs incurred by the public payer. We used the costs valid in December 2013. The paper presents the estimated costs of treatment of side effects related to the pulmonology disease area. Taking into account the costs incurred by the NHF and the patient separately e calculated the total spending and the percentage of each component cost in detail. The treatment of adverse drug reactions generates a significant cost incurred by both the public payer and the patient.

Refine search results

2 Current Issues in Pharmacy and Medical Sciences

2 2014

2 Drozd M.

2 Janowska A.

2 Kiepurska N.

2 Paluchowska B.

2 Paprzycki P.

2 Szkultecka-Debek M.

1 Adamczyk-Korbel M.

1 Drozd K.

1 Jahnz-Rozyk K.

1 Mazurek J.

Search results

An adverse events potential costs analysis based on Drug Programs in Poland. Dermatology focus

An analysis of potential costs of adverse events based on Drug Programs in Poland. Pulmonology focus